复宏汉霖PD-L1 ADC HLX43获美国FDA孤儿药资格认定

南方财经网
Oct 20, 2025

  南方财经10月20日电,复宏汉霖宣布,公司创新型程序性死亡-配体1(PD-L1)抗体偶联药物(ADC)注射用HLX43已获得美国食品药品监督管理局(FDA)授予的孤儿药资格认定(Orphan Drug Designation, ODD),用于胸腺上皮肿瘤(Thymic Epithelial Tumors,TETs)的治疗。胸腺癌是胸腺上皮肿瘤中一类相对罕见但侵袭性强、预后较差的恶性肿瘤,现有后线治疗方案疗效不佳,存在较大的未满足临床需求。

(文章来源:南方财经网)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10